Shares of Immunomedics, Inc. (IMMU) have traded between $11.6 – 22.23. The next earnings date is set for Feb 24, 2020. Let’s see how its prospects are shaping up.

What does Immunomedics, Inc.(IMMU) do?

Immunomedics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. It operates through the United States, and Europe geographical segments. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

IMMU Insider Trading Insight

On 2019-12-05, Avoro Capital Advisors LLC See Remarks, 10% purchased 2,000,000 shares of IMMU. That represents a value of $24,513,516. Not to be outdone, on 2019-10-02, Avoro Capital Advisors LLC P – Purchase bought1,500,000 shares of IMMU. These insiders are clearly in the know because they work closely with the company.

The ACMR Consensus Price Target

The mean recommendation of ACM Research, Inc. from top Wall Street analysts is a Strong Buy. That is based on 7 analysts who work on the Street. Based on 7 analysts offering 12 month price targets for ACM Research in the last 3 months. The average price target is $39.71 with a high forecast of $70.00 and a low forecast of $30.00. The average price target represents a -18.14% decrease from the last price of $48.51. Last week, several articles were published in financial papers about ACMR and 38% Bearish while 63% Bullish.

Looking for stocks similar to IMMU and ACMR?

Here are some stocks to consider:
NAVB
SGEN